Giovanni Frisoni

Best outcome measures for Alzheimer’s disease follow-up in the clinic

Exploring the potential role of amyloid deposition in the gut in Alzheimer’s disease

Defining subgroups of patients with subjective cognitive decline more likely to progress

European task force recommendations: shifting memory clinics towards prevention

Reframing the way we think about Alzheimer’s disease

Revising the amyloid hypothesis in Alzheimer’s disease: the probabilistic model

Blood-based biomarkers for Alzheimer’s disease screening

Ethical considerations of biomarker use in prodromal Alzheimer’s disease

The landscape of biomarkers for the management of Alzheimer’s disease

Task force from Geneva: Roadmap for biomarker validation in Alzheimer’s disease